GSK's London-listed shares fell about 2% on Friday after the U.S. Food and Drug Administration approved only one of two treatment combinations with the British firm's blood cancer drug, limiting the ...

Shortly following the announcement of its acquisition of Syndivia’s ADC, GSK entered into a worldwide exclusive license agreement with Empirico for its leading clinical-stage respiratory disease ...

WAVE Life Sciences Ltd (WVE) showcases significant progress in RNA technologies and a strong financial position, despite ...

London: GSK plc and Empirico Inc., a clinical-stage biotechnology company with capabilities in human genetics-driven target ...

GSK said the forecasts were “inclusive of tariffs enacted thus far and indicated potential European tariffs' impact of 15 per ...

GSK plc ( GSK) Q3 2025 Earnings Call October 29, 2025 8:00 AM EDT Ladies and gentlemen, a very warm welcome to the GSK Q3 2025 Results Call. I'm delighted to be joined today by Emma Walmsley, Luke ...

Vietnam Vaccine JSC (VNVC) and GSK Vietnam have strengthened their strategic partnership to accelerate access to new ...

Under the deal, France-based Syndivia will receive an upfront payment, as well as development and commercial milestone payments, totaling up to £268 million. ・GSK, meanwhile, will undertake ...

In addition, GSK said GSK576422, its B7-H3-targeted antibody-drug conjugate has received orphan drug designation from the European Medicines Agency for the treatment of pulmonary neuroendocrine ...

A bold guidance raise, fresh FDA approval, and pipeline deals set the stage for GSK's post-Walmsley transformation.

"Sales grew in all areas, with particularly strong performances in Specialty Medicines, driven by double-digit growth in Respiratory Inflammation & Immunology, Oncology and HIV," said Emma Walmsley, ...

British pharmaceutical group GSK on Wednesday raised its full-year outlook after strong sales growth in its third quarter, ...